EGFR and non-small cell lung carcinoma: An example from this section is a phase II clinical trial examining the safety and effectiveness of a combination therapy consisting of Afatinib, which targets EGFR mutations, and nesitumumab, which targets the EGFR pathway, in patients with advanced NSCLC.